fluorodeoxyglucose f18 has been researched along with nintedanib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bondue, B; Castiaux, A; Doumont, G; Egrise, D; Goldman, S; Huaux, F; Lacroix, S; Mathey, C; Sherer, F; Van Simaeys, G | 1 |
| Aide, N; Alexandre, J; Berton, D; Bonichon, N; Combe, P; Coquan, E; De Rauglaudre, G; Fauchille, P; Ferron, G; Joly, F; Leary, A; Meunier, J; Pujade Lauraine, E | 1 |
2 other study(ies) available for fluorodeoxyglucose f18 and nintedanib
| Article | Year |
|---|---|
Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients.
Topics: Aged; Animals; Antineoplastic Agents; Female; Fibrosis; Fluorodeoxyglucose F18; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Mice; Mice, Inbred C57BL; Middle Aged; Positron Emission Tomography Computed Tomography; Prospective Studies; Pyridones | 2019 |
Predicting tumor response and outcome of second-look surgery with
Topics: Female; Fluorodeoxyglucose F18; Humans; Indoles; Neoadjuvant Therapy; Ovarian Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prognosis; Second-Look Surgery; Treatment Outcome; Tumor Burden | 2021 |